Patrick J. Balthrop Sr., MBA, Agendia.
Agendia Inc, Irvine, Calif, has appointed Patrick J. Balthrop Sr., former CEO of Luminex, as nonexecutive chairman.
“Patrick’s knowledge and experience in driving rapid growth in technology-led companies is exceptional, and will bolster Agendia’s position in the sector,” says Mark R. Straley, CEO of Agendia. “Agendia is committed to improving the quality of life for cancer patients through molecular diagnostics, one patient at a time, and we are convinced that Patrick’s expertise will help us to achieve this. We warmly welcome him to the role of chairman.”
Agendia’s primary focus is expanding the adoption of clinically useful genetic signatures as an aid to personalizing breast cancer treatment by increasing the geographic reach and reimbursement of these panels, such as its proven MammaPrint 70-gene breast cancer risk-of-recurrence test. MammaPrint is available globally through many major hospitals to provide physicians and patients access to essential breast cancer screening, enabling more informed decisionmaking and more individualized treatment.
“Agendia’s strong vision for transforming breast cancer treatment is inspiring, and I look forward to working with the team at this pivotal time for the company,” says Balthrop.
Balthrop is currently a director at Oxford Immunotec Global, Personalis Inc, and Concert Genetics. He is an advisor to Water Street Healthcare Partners and the founding principal of Apalachee Ventures, an investment and advisory firm. Balthrop previously held positions of CEO, president, and director at Luminex, and president at Fisher Healthcare (then Fisher Scientific). He has also held a number of positions within Abbott Laboratories, including president of Abbott Vascular and corporate vice president of worldwide commercial operations.
Balthrop has an MBA from the Kellogg School of Management at Northwestern University and a BS in biology from Spring Hill College.
